KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Receivables: 2020-2025

Historic Receivables for Esperion Therapeutics (ESPR) over the last 5 years, with Sep 2025 value amounting to $119.0 million.

  • Esperion Therapeutics' Receivables rose 75.42% to $119.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $388.2 million, marking a year-over-year increase of 67.82%. This contributed to the annual value of $80.1 million for FY2024, which is 65.26% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Receivables is $119.0 million, which was up 10.43% from $107.7 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Receivables registered a high of $119.0 million during Q3 2025, and its lowest value of $21.7 million during Q3 2021.
  • Moreover, its 3-year median value for Receivables was $60.4 million (2024), whereas its average is $67.2 million.
  • Data for Esperion Therapeutics' Receivables shows a peak YoY skyrocketed of 85.13% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' Receivables stood at $22.9 million in 2021, then surged by 47.07% to $33.7 million in 2022, then surged by 43.78% to $48.5 million in 2023, then skyrocketed by 65.26% to $80.1 million in 2024, then surged by 75.42% to $119.0 million in 2025.
  • Its last three reported values are $119.0 million in Q3 2025, $107.7 million for Q2 2025, and $81.3 million during Q1 2025.